12+

ChronicCoronaryHeartDiseaseWho Needs Enhanced Antithrombotic Therapy?

The article considers the concept of «chronic coronary heart disease», shows the mechanisms of its development, describes the assessment and treatment of coronary heart disease, which has changed significantly over the past decade. The problem of comorbidity, which is very relevant in the context of the management of patients with coronary heart disease, is investigated. The European recommendations for comorbid patients with coronary heart disease for the treatment and prevention of CV diseases in patients with DM, developed in cooperation with the European Association for the Study of Diabetes Mellitus, are considered. The necessity of adding a second anticoagulant to acetylsalicylic acid for patients with acute coronary syndrome without a high risk of bleeding for long-term secondary prevention is considered. The new recommendations describe the need to prescribe a combination of new oral anticoagulants and acetylsalicylic acid in patients with DM and recurrent peripheral artery disease of the lower extremities, provided there is no high risk of bleeding. The role of antithrombotic therapy in the treatment of patients with chronic coronary heart disease has been shown. It is shown who is prescribed enhanced antithrombotic therapy for coronary heart disease.

DOI: 10.52575/2687-0940-2022-45-3-263-272
Number of views: 505 (view statistics)
Number of downloads: 357
Full text (HTML)Full text (PDF)To articles listTo category
  • User comments
  • Reference lists

While nobody left any comments to this publication.
You can be first.

Leave comment: